Company intelligence / Profile preview

NTC Pharma

Ownership: Private
Employees: ~249
Development stage: Commercial

Overview

NTC has conducted clinical trials involving thousands of patients, particularly in ophthalmology. Their study demonstrated the non-inferiority of NTC014 (antibiotic and NSAID combination) compared to an antibiotic alone for bacterial conjunctivitis, despite using a lower dose of antibiotic[1].

Therapeutic areas: GastroenterologyInfectious DiseasesOphthalmologyWomen's Health
Modalities: Drugsmedical devicesfood supplements
Industry: Biotech

Drug pipeline

8 assets

Hy-ter

7 more assets in the full pipeline.

Request access →

Partnerships

Distributors and partners in over 100 countries

Beyond the preview

Go deeper on NTC Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTC Pharma.

Explore the full profile